These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 30606204)

  • 1. Letrozole-associated controlled ovarian hyperstimulation in breast cancer patients versus conventional controlled ovarian hyperstimulation in infertile patients: assessment of oocyte quality related biomarkers.
    Goldrat O; Van Den Steen G; Gonzalez-Merino E; Dechène J; Gervy C; Delbaere A; Devreker F; De Maertelaer V; Demeestere I
    Reprod Biol Endocrinol; 2019 Jan; 17(1):3. PubMed ID: 30606204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review.
    Rodgers RJ; Reid GD; Koch J; Deans R; Ledger WL; Friedlander M; Gilchrist RB; Walters KA; Abbott JA
    Hum Reprod; 2017 May; 32(5):1033-1045. PubMed ID: 28333356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients.
    Goldrat O; Gervy C; Englert Y; Delbaere A; Demeestere I
    Hum Reprod; 2015 Sep; 30(9):2184-9. PubMed ID: 26109617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer-a prospective nationwide Swedish multicenter study.
    Marklund A; Eloranta S; Wikander I; Kitlinski ML; Lood M; Nedstrand E; Thurin-Kjellberg A; Zhang P; Bergh J; Rodriguez-Wallberg KA
    Hum Reprod; 2020 Apr; 35(4):929-938. PubMed ID: 32313940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is letrozole during ovarian stimulation useful in breast cancer patients undergoing fertility preservation to reduce early luteal progesterone levels following GnRH-agonist trigger?
    Lalami I; Labrosse J; Cedrin-Durnerin I; Comtet M; Vinolas C; Krief F; Sifer C; Peigne M; Grynberg M
    Reprod Biol Endocrinol; 2022 Jun; 20(1):87. PubMed ID: 35690817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Oocyte and Embryo Quality Between Random Start and Controlled Ovarian Stimulation Cycles in Cancer Patients Undergoing Fertility Preservation.
    İsrafilova G; Şükür YE; Özkavukcu S; Sönmezer MA; Atabekoğlu CS; Özmen B; Berker B; Aytaç R; Koç A; Sönmezer M
    Reprod Sci; 2021 Aug; 28(8):2200-2207. PubMed ID: 33409878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies.
    Meirow D; Raanani H; Maman E; Paluch-Shimon S; Shapira M; Cohen Y; Kuchuk I; Hourvitz A; Levron J; Mozer-Mendel M; Brengauz M; Biderman H; Manela D; Catane R; Dor J; Orvieto R; Kaufman B
    Fertil Steril; 2014 Aug; 102(2):488-495.e3. PubMed ID: 24934489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Random-start controlled ovarian hyperstimulation with letrozole for fertility preservation in cancer patients: case series and review of literature.
    Keskin U; Ercan CM; Yilmaz A; Babacan A; Korkmaz C; Duru NK; Ergun A
    J Pak Med Assoc; 2014 Jul; 64(7):830-2. PubMed ID: 25255597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization.
    Azim AA; Costantini-Ferrando M; Lostritto K; Oktay K
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2197-200. PubMed ID: 17356042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A simplified universal approach to COH protocol for IVF: ultrashort flare GnRH-agonist/GnRH-antagonist protocol with tailored mode and timing of final follicular maturation.
    Orvieto R
    J Ovarian Res; 2015 Nov; 8():69. PubMed ID: 26536862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian tissue cryopreservation can be combined simultaneously with oocyte retrieval after controlled ovarian hyperstimulation.
    Puy V; Dupeux M; Mayeur A; Grynberg M; Benoit A; Bendayan M; Zhegari F; Hesters L; Gallot V; Prevot S; Frydman N; Sonigo C
    Hum Reprod; 2023 May; 38(5):860-871. PubMed ID: 36860186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience.
    Reddy J; Turan V; Bedoschi G; Moy F; Oktay K
    J Assist Reprod Genet; 2014 Jul; 31(7):927-32. PubMed ID: 24854484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of letrozole on follicular fluid steroids concentrations in cancer patients undergoing oocyte cryopreservation.
    Dallagiovanna C; Reschini M; Polledri E; Pinna M; Ciaffaglione M; Cuce' V; Somigliana E; Fustinoni S; Filippi F
    J Assist Reprod Genet; 2022 May; 39(5):1169-1176. PubMed ID: 35348950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of letrozole administration on oocyte morphology in breast cancer patients undergoing fertility preservation.
    Bercaire LMN; Cavagna M; Donadio NF; Rocha AR; Portela R; Alves VR; Santos TBB; Cavagna F; Dzik A; Gebrim LH; Nahas EAP
    JBRA Assist Reprod; 2020 Jul; 24(3):257-264. PubMed ID: 32293820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting successful induction of oocyte maturation after gonadotropin-releasing hormone agonist (GnRHa) trigger.
    Kummer NE; Feinn RS; Griffin DW; Nulsen JC; Benadiva CA; Engmann LL
    Hum Reprod; 2013 Jan; 28(1):152-9. PubMed ID: 23077235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antral follicle responsiveness to FSH, assessed by the follicular output rate (FORT), is altered in Hodgkin's lymphoma when compared with breast cancer candidates for fertility preservation.
    Sonigo C; Comtet M; Duros S; Sifer C; Sermondade N; Grynberg M
    J Assist Reprod Genet; 2018 Jan; 35(1):91-97. PubMed ID: 28986734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of controlled ovarian hyperstimulation with or without letrozole for fertility preservation in breast cancer patients: A multicenter retrospective study.
    Goldrat O; De Cooman M; Mailliez A; Delbaere A; D'Orazio E; Demeestere I; Decanter C
    Eur J Cancer; 2022 Oct; 174():134-141. PubMed ID: 35998549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist cycles.
    Lee JR; Kim SH; Kim SM; Jee BC; Ku SY; Suh CS; Choi YM; Kim JG; Moon SY
    Fertil Steril; 2008 Apr; 89(4):860-7. PubMed ID: 18249372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of letrozole or tamoxifen coadministered with a standard stimulation protocol on fertility preservation among breast cancer patients.
    Shulman Y; Almog B; Kalma Y; Fouks Y; Azem F; Cohen Y
    J Assist Reprod Genet; 2021 Mar; 38(3):743-750. PubMed ID: 33409757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of letrozole on oocyte quality in assisted reproductive technology (ART); a randomized double-blind clinical trial.
    Hossein Rashidi B; Shahrokh Tehraninejad E; Amanpour S; Bandarian F; Bandarian M
    Gynecol Endocrinol; 2022 Dec; 38(12):1087-1092. PubMed ID: 36562249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.